Magyar Telekom and OTP are the top picks.
'Buy' rating remains.
Profit doubled, yet share price is falling.
Analysts expect major profit growth for Q416.
Levosert goes to Europe.
In female healthcare product acquistions.
Negotiating the curves of the biosimilar scene.
The rating is 'Buy'.
Brighter hopes for Russia.
Profit guidance raised for 2016.
80% growth seen in net profit.